We’d love your feedback!

We’re working on new tools and we want to make sure they’re truly useful to you.

Can you spare 30 seconds to answer 3 quick questions?

Your feedback directly shapes the future of Finviz.

Take the Survey

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
May 16 03:35PM ET
2.88
Dollar change
+0.07
Percentage change
2.49
%
Index- P/E- EPS (ttm)-4.68 Insider Own0.27% Shs Outstand9.03M Perf Week23.87%
Market Cap26.01M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float9.00M Perf Month-0.69%
Income-48.12M PEG- EPS next Q- Inst Own23.84% Short Float0.44% Perf Quarter-53.09%
Sales71.67M P/S0.36 EPS this Y- Inst Trans12.08% Short Ratio1.31 Perf Half Y-14.29%
Book/sh8.81 P/B0.33 EPS next Y- ROA-35.92% Short Interest0.04M Perf Year-64.91%
Cash/sh7.92 P/C0.36 EPS next 5Y- ROE-51.22% 52W Range2.18 - 8.43 Perf YTD-57.33%
Dividend Est.- P/FCF- EPS past 5Y-0.09% ROI-57.72% 52W High-65.84% Beta0.71
Dividend TTM- Quick Ratio2.68 Sales past 5Y6.12% Gross Margin70.26% 52W Low32.11% ATR (14)0.34
Dividend Ex-Date- Current Ratio2.92 EPS Y/Y TTM48.12% Oper. Margin-62.45% RSI (14)46.27 Volatility13.10% 11.77%
Employees674 Debt/Eq0.09 Sales Y/Y TTM-5.72% Profit Margin-67.15% Recom1.00 Target Price73.05
Option/ShortNo / Yes LT Debt/Eq0.05 EPS Q/Q50.11% Payout- Rel Volume0.91 Prev Close2.81
Sales Surprise- EPS Surprise- Sales Q/Q4.65% EarningsDec 04 BMO Avg Volume30.43K Price2.88
SMA206.63% SMA50-23.39% SMA200-42.13% Trades Volume26,275 Change2.49%
Date Action Analyst Rating Change Price Target Change
Oct-15-21Resumed Cowen Outperform
Jul-07-20Initiated Cowen Outperform
Mar-25-25 07:45AM
Dec-31-24 04:56AM
Dec-05-24 06:29AM
Dec-03-24 11:59PM
06:45AM
11:16PM Loading…
Oct-10-24 11:16PM
Sep-27-24 08:37AM
Aug-22-24 11:59PM
Aug-19-24 02:21AM
Jun-03-24 12:41AM
May-30-24 08:02AM
03:42AM
May-29-24 11:20PM
09:52AM
01:34AM
02:00AM Loading…
May-23-24 02:00AM
May-14-24 02:02AM
Apr-29-24 03:30AM
Apr-26-24 01:59AM
Mar-30-24 12:39AM
Mar-28-24 10:52PM
05:16PM
Jan-04-24 01:03AM
Dec-19-23 09:35PM
Dec-01-23 08:39AM
02:21AM
Nov-30-23 01:25AM
Nov-22-23 02:04AM
Nov-20-23 08:55PM
Oct-30-23 03:20AM
07:18PM Loading…
Oct-15-23 07:18PM
Sep-07-23 10:43PM
Sep-01-23 08:46AM
Aug-31-23 09:03PM
01:30AM
Aug-04-23 03:27AM
Jun-28-23 04:05AM
Jun-09-23 01:47PM
Jun-08-23 12:20AM
May-31-23 12:53PM
04:36AM
May-30-23 09:40AM
12:53AM
May-24-23 08:42AM
Apr-27-23 01:01AM
Apr-20-23 10:43PM
Apr-17-23 09:59AM
Mar-30-23 08:28AM
Mar-28-23 02:08AM
Mar-19-23 08:47AM
Mar-14-23 09:44AM
Mar-07-23 03:38AM
Jan-17-23 08:37PM
Jan-16-23 08:36AM
Jan-03-23 09:25AM
Dec-27-22 09:10AM
Dec-15-22 06:52AM
Nov-21-22 12:00PM
Nov-15-22 09:20PM
Nov-10-22 05:15AM
Nov-01-22 06:10AM
Oct-27-22 07:50AM
Oct-25-22 12:46AM
Oct-21-22 01:01PM
Oct-10-22 06:25AM
Sep-08-22 04:56AM
Aug-31-22 04:30PM
01:24PM
07:05AM
05:29AM
Aug-09-22 07:46AM
Aug-04-22 09:10AM
Aug-03-22 02:12AM
Jul-14-22 09:50PM
Jul-08-22 06:49AM
Jun-30-22 10:57AM
Jun-24-22 03:26AM
Jun-21-22 02:03AM
01:59AM
Jun-15-22 08:01AM
Jun-01-22 07:49AM
May-31-22 01:30PM
02:32AM
May-16-22 04:00AM
May-05-22 06:45PM
May-02-22 11:43AM
Mar-31-22 05:46AM
Mar-22-22 04:30PM
Mar-21-22 08:30PM
Mar-16-22 06:54PM
Mar-15-22 09:38AM
07:29AM
Mar-02-22 10:29AM
Feb-21-22 11:30PM
Jan-17-22 03:38PM
02:38PM
Dec-28-21 08:05PM
Dec-27-21 10:00PM
Dec-10-21 06:38PM
Nov-17-21 08:15PM
Burning Rock Biotech Ltd. engages in the investment of medical fields. It specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. The firm operates through the following segments: Central Laboratory Business, In-Hospital Business and Pharma Research and Development Services. Its products and clinical applications include companion diagnostics for targeted therapy and immunotherapy, benign, malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction and tumor susceptibility tests. The company was founded by Yu Sheng Han in January 2014 and is headquartered in Guangzhou, China.